NAFLD患者他汀使用率及相关因素:TARGET-NASH研究
本研究基于TARGET-NASH真实世界队列,评估非酒精性脂肪性肝病(NAFLD)患者中有他汀适应症者的使用率及相关患者因素。背景指出他汀在肝病患者中安全且与较低死亡、失代偿及可能降低肝细胞癌风险相关,但因肝毒性担忧存在处方不足。
要点
- NAFLD患者心血管风险升高,他汀可降低心血管事件风险。
- 他汀在肝病患者(含代偿期肝硬化)中安全,与较低死亡和失代偿相关。
- 因肝毒性担忧,肝病患者他汀存在处方不足。
核心结论
- 研究旨在评估NAFLD患者中有适应症的他汀使用率及相关患者因素。
研究设计与样本
- 基于TARGET-NASH真实世界队列的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of cardiovascular disease. Hydoxy-3-methyglutaryl-coenzyme reductase inhibitors, statins, reduce the risk of cardiovascular events.1 Studies have shown that statins are safe among patients with liver disease, including those with compensated cirrhosis,2 and their use is associated with lower mortality, hepatic decompensation, and possibly hepatocellular carcinoma.3,4 Despite these data, statins are under prescribed among patients with liver disease due to concerns about hepatotoxicity.5 This study aimed to assess prevalence and patient factors associated with indicated statin use in patients with NAFLD in a real-world cohort.
引用
- Thomson MJ, Serper M, Khungar V, et al. Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study. Clin Gastroenterol Hepatol. 2021. PMID: 33775894. doi:10.1016/j.cgh.2021.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。